<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758107</url>
  </required_header>
  <id_info>
    <org_study_id>monorapa</org_study_id>
    <nct_id>NCT01758107</nct_id>
  </id_info>
  <brief_title>Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients</brief_title>
  <official_title>Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <authority>Thailand: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study safety of longterm immunosuppressive protocol with Sirolimus plus Prednisolone, and
      Calcineurin inhibitor withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sirolimus with Cyclosporine minimization is the standard protocol for kidney transplantation
      in Chulalongkorn University. The investigators published the safety of this regimen in
      Transplantation Proceeding 2008; 40: 2206-8.

      The investigators now further study in those patients who doing well with this regimen more
      than 1 year. The patients will be asked for kidney biopsy to evaluate and make sure they
      don't have subclinical rejection. The patients who don't have subclinical rejection will
      discontinue cyclosporine and continue with only sirolimus and prednisolone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>longterm glomerular filtration rate defined by eGFR CKD-EPI</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute rejection rate</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Sirolimus with Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus with Prednisolone, and withdraw cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus with Cyclosporine with Prednisolone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Withdraw cyclosporine</intervention_name>
    <arm_group_label>Sirolimus with Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant with Sirolimus plus Cyclosporine plus Prednisolone more than 1 year

        Exclusion Criteria:

          -  history of acute rejection, or subclinical rejection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natavudh Townamchai, MD</last_name>
    <phone>+66894904222</phone>
    <email>ntownamchai@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natavudh Townamchai, MD</last_name>
      <phone>+66894904222</phone>
      <email>ntownamchai@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Natavudh Townamchai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <lastchanged_date>December 31, 2012</lastchanged_date>
  <firstreceived_date>December 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Natavudh Townamchai, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
